Logo Image
Opinion|Videos|August 9, 2024

Challenges of PSA as a Diagnostic Biomarker

The key opinion leaders explore the challenges and limitations associated with using prostate-specific antigen (PSA) as a biomarker for prostate cancer detection and monitoring.

Episodes in this series

Video content above is prompted by the following question:

  • What are some challenges or limitations in using PSA as a biomarker?

Related Content

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more